Kneeland Youngblood - Mallinckrodt Plc Independent Director

MNKDelisted Stock  USD 0.34  0.00  0.00%   

Director

Dr. Kneeland C. Youngblood, M.D., is Independent Director of Mallinckrodt Public Limited Company. Dr. Youngblood is a founding partner of Pharos Capital Group, a private equity firm that focuses on providing growth and expansion capitalbuyouts in healthcare, business services and opportunistic investments. Dr. Youngblood served as a director of Gap Inc. from 2006 to 2012, a director of Starwood Hotels and Resorts from 2001 to 2012, a director of Burger King Corporation from 2004 to 2010 and a director of iStar Financial from 1998 to 2001. Dr. Youngblood was serving as a director of Energy Future Holdings Corporationration an electric utility provider, since 2007 and a director of Pace Holdings Corporationration II, a company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, since 2017. He also serves as a director on the Dallas Police Fire Pension Fund, since 2017. Prior to that, Dr. Youngblood served as a director of Pace Holdings Corporationration from 2015 to 2017. Dr. Youngbloods qualifications to serve on our Board include his extensive experience in healthcare practice, policy and business. since 2013.
Age 63
Tenure 11 years
Professional MarksPh.D
Phone353 1 696 0000
Webhttps://www.mallinckrodt.com
Youngblood earned a B.A. in politics from Princeton University and an M.D. from the University of Texas Southwestern Medical School.

Mallinckrodt Plc Management Efficiency

Mallinckrodt Plc's management efficiency ratios could be used to measure how well Mallinckrodt Plc manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 3.07 B in debt with debt to equity (D/E) ratio of 1.44, which is OK given its current industry classification. Mallinckrodt Plc has a current ratio of 2.92, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Mallinckrodt Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Mallinckrodt Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mallinckrodt Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mallinckrodt to invest in growth at high rates of return. When we think about Mallinckrodt Plc's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Bronwen EvansCronos Group
48
John FisherStampAurora Cannabis
N/A
Frank FallwellSNDL Inc
N/A
Jake NunnJourney Medical Corp
47
Jason AdlerCronos Group
46
Frederick CravesJourney Medical Corp
72
Brian HalakAlimera Sciences
45
Adam SzwerasAurora Cannabis
48
Toan DoAurora Cannabis
41
William RingoJourney Medical Corp
72
Toai NguyenAurora Cannabis
58
Tuan DamAurora Cannabis
60
David CohenJourney Medical Corp
53
Peter PizzoAlimera Sciences
50
John SnisarenkoAlimera Sciences
N/A
Tai BuiAurora Cannabis
N/A
David LazzaratoCanopy Growth Corp
64
Murray GoldmanCanopy Growth Corp
N/A
Charles RificiAurora Cannabis
N/A
Mary SzelaAlimera Sciences
55
Chris SchnarrCanopy Growth Corp
48
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. The company was founded in 1867 and is based in Dublin, Ireland. Mallinckrodt Plc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on AMEX Exchange. It employs 2778 people. Mallinckrodt Plc (MNK) is traded on NYSE MKT Exchange in USA and employs 2,673 people.

Management Performance

Mallinckrodt Plc Leadership Team

Elected by the shareholders, the Mallinckrodt Plc's board of directors comprises two types of representatives: Mallinckrodt Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mallinckrodt. The board's role is to monitor Mallinckrodt Plc's management team and ensure that shareholders' interests are well served. Mallinckrodt Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mallinckrodt Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Gary Phillips, Executive Vice President and Chief Strategy Officer
Steven Romano, Executive Vice President and Chief Scientific Officer
Mark Casey, Executive Vice President and Chief Legal Officer
JoAnn Reed, Independent Director
Virgil Thompson, Independent Director
Lisa French, Ex Officer
Stephen Welch, Ex Generics
Henriette Nielsen, Ex Officer
Steven MD, Ex Officer
Diane Gulyas, Independent Director
Joseph Zaccagnino, Independent Director
Paul Carter, Independent Director
David Carlucci, Independent Director
CPA CPA, Global Officer
George Kegler, CFO, Executive Vice President
Frank Scholz, Executive Vice President and Chief Operations and Digital Innovation Officer
David Norton, Independent Director
Hugh ONeill, Executive Vice President and President, Autoimmune and Rare Diseases
Martin Carroll, Independent Director
Steve Romano, Senior Vice President Chief Scientific Officer
Sigurdur Olafsson, Pres CEO
Mark Trudeau, CEO and President Director and Member of Portfolio Committee
Kneeland Youngblood, Independent Director
Bryan Reasons, Chief Financial Officer, Executive Vice President
J Carroll, Independent Director
Meredith Fischer, Senior Vice President - Communications and Public Affairs
Kassie Harrold, Ex Officer
Jason Goodson, Exec Devel
Terrance Carlson, Senior Vice President and General Counsel - Interim
Ian Watkins, Chief Human Resource Officer, Executive Vice President
Dagmar RosaBjorkeson, Chief Strategy and Corporate Development Officer
Melvin Booth, Independent Chairman of the Board
Raymond Furey, Senior Vice President Chief Compliance Officer
Angus Russell, Independent Non-Executive Chairman of the Board
Ronald Lloyd, Executive Vice President and President - Hospital Therapies
Karen Sheehy, Chief Compliance Officer
Matthew Harbaugh, CFO and Sr. VP
MichaelBryant Hicks, General Counsel
Carlos Paya, Independent Director
Anne Whitaker, Independent Director
Mark Tyndall, Chief VP

Mallinckrodt Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mallinckrodt Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Mallinckrodt Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Mallinckrodt Plc's short interest history, or implied volatility extrapolated from Mallinckrodt Plc options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Consideration for investing in Mallinckrodt Stock

If you are still planning to invest in Mallinckrodt Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mallinckrodt Plc's history and understand the potential risks before investing.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Transaction History
View history of all your transactions and understand their impact on performance
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Volatility Analysis
Get historical volatility and risk analysis based on latest market data